Press Releases :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

Year

Category

Sep 23, 2014 9:17 am EDT

OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints

Sep 11, 2014 9:00 am EDT

Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference

Sep 8, 2014 12:20 pm EDT

OPKO Licensee TESARO Submits New Drug Application for Rolapitant

Aug 11, 2014 4:48 pm EDT

OPKO Announces Second Quarter Operating and Financial Results

Aug 11, 2014 4:15 pm EDT

Rayaldee Phase 3 Trial Meets Primary Endpoints

Aug 7, 2014 3:35 pm EDT

OPKO Submits IND for Rayaldee™ as Adjunctive Cancer Therapy

Aug 7, 2014 8:30 am EDT

OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014 Financial Results on August 11, 2014

Jul 22, 2014 10:41 am EDT

OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE

Jul 9, 2014 1:23 pm EDT

OPKO's Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe

Jun 27, 2014 9:54 am EDT

OPKO Granted Patent from European Patent Office for Lagova™